About the Company
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax (Anthrax Vaccine Adsorbed), the only anthrax vaccine licensed by the U.S. Food and Drug Administration (FDA) and Narcan (naloxone) for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EBS News
Institutional owners may take dramatic actions as Emergent BioSolutions Inc.'s (NYSE:EBS) recent 16% drop adds to one-year losses
Key Insights Significantly high institutional ownership implies Emergent BioSolutions' stock price is sensitive ...
Emergent BioSolutions gets grant for treatment of viral infection using morphic form ii phosphonic acid
Discover the groundbreaking patent by Emergent BioSolutions for synthesizing phosphonate ester compounds to treat viral infections. Learn about the innovative method and its potential impact on ...
Emergent BioSolutions Inc. (NYSE:EBS) Q4 2023 Earnings Call Transcript
Emergent BioSolutions Inc. misses on earnings expectations. Reported EPS is $-0.77 EPS, expectations were $-0.33. Emergent ...
Why this Maryland biotech furloughed 130 workers in Michigan
Emergent BioSolutions Inc. (NYSE: EBS) has furloughed 130 employees in Lansing, Michigan, whose work hinges on the federal government buying more doses of its recently greenlit anthrax vaccine ...
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI ...
Emergent BioSolutions Inc EBS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Emergent BioSolutions Inc. (NYSE:EBS) Q4 2023 Earnings Call Transcript
Emergent BioSolutions Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, […] Reported EPS is $-0.77 EPS, ...
emergent biosolutions inc.
Production of Johnson & Johnson’s (JNJ.N) COVID-19 vaccine at a U.S. manufacturing plant was halted by the U.S. Food and Drug Administration while the agency ...
Emergent BioSolutions Inc (ER4.BE)
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of DirectorsWARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive ...
Loading the latest forecasts...